Subscribe to NRx Newsletter


NRx Weekly Newsletter: January 28, 2022

At NRx, we focus on developing medicines and a vaccine to help some of the sickest patients return home to their families and prevent people from contracting the COVID-19 virus. Each week we work in large and small ways to advance our efforts around the world, and it’s our goal to update those interested in […]

Aviptadil Right to Try – for US-licensed physicians who wish to obtain Aviptadil under Right to Try law for Critical COVID-19 patients with no therapeutic alternative

At NRx Pharmaceuticals, we are committed to including patients in need of potentially lifesaving cures in our development programs at the earliest opportunity. During the initial stages of development, this may take the form of “named patient” Investigational New Drug licensing that must be approved by the US Food and Drug Administration (FDA) on an individual basis. As development continues, we may initiate Expanded Access programs (previously known as compassionate care) with the encouragement of the FDA.